Cargando…
ELABELA acts as a protective biomarker in patients with atrial fibrillation
BACKGROUND: Atrial fibrillation (AF) is the most common type of clinical arrhythmia. An early diagnosis can be beneficial in the prevention of complications, such as heart failure (HF) and stroke. In this study, we revealed that ELABELA (ELA) acts as a protective factor in patients with arrhythmia a...
Autores principales: | Cui, Chunhong, Zhou, Hongmei, Xu, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743407/ https://www.ncbi.nlm.nih.gov/pubmed/35070372 http://dx.doi.org/10.21037/jtd-21-1728 |
Ejemplares similares
-
Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study
por: Ma, Zheng, et al.
Publicado: (2021) -
Interaction of apelin, elabela and nitric oxide in schizophrenia patients
por: Catak, Zekiye, et al.
Publicado: (2020) -
Peptide hormone ELABELA enhances extravillous trophoblast differentiation, but placenta is not the major source of circulating ELABELA in pregnancy
por: Georgiadou, Danai, et al.
Publicado: (2019) -
Elabela gene therapy promotes angiogenesis after myocardial infarction
por: Jin, Liangli, et al.
Publicado: (2021) -
Serum Elabela Level Significantly Increased in Patients with Complete Heart Block
por: Acele, Armağan, et al.
Publicado: (2020)